Suppression of Thioacetamide-Induced Hepatic Injury in Rats treatment with Resveratrol: Role of mammalian Target of Rapamycin (mTOR) Cell Signaling

Dallak, Mohammad; Al‐Hashem, Fahaid; Haidara, Mohamed A; Ellatif, Mohamed Abd; Kamar, Samaa S; ShamsEldeen, Asmaa Mohammed; Dawood, Amal F; Ebrahim, Hasnaa Ali

doi:10.4067/s0717-95022020000300558

Cited by 3 publications

(2 citation statements)

References 21 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed the promising efficacy of resveratrol in TAA-induced liver failure based on serum markers, pathological evaluations, and neurobehavioral manifestations of HE. Based on the previously published literature along with the outcome of the current research, we believe that this agent, with its anti-inflammatory and antioxidant properties, can play a noticeable role as an alternative supplement in patients suffering from liver failure (11)(12)(13). In the present investigation, laboratory parameters, including AST and ALT, as indicators of liver damage, seemed to be lower in resveratrol-treated rats than in the untreated group.…”

Section: Discussionsupporting

confidence: 56%

“…Resveratrol, a natural antioxidative and antiinflammatory agent, has shown to possess anti-platelet, anti-cholesterol, anti-viral, anti-aging, anti-cancer, and neuroprotective effects, as well as hepatoprotective effects, both in vivo and in vitro (11)(12)(13). Several studies have investigated the hepatoprotective role of resveratrol, showing that it can inhibit the progression of hepatic diseases in various models of liver damage, including alcoholic/non-alcoholicnon-alcoholic fatty liver, ethanolinduced/dimethylnitrosamine-induced liver failure, and TAA-induced chronic liver damage (13)(14)(15)(16)(17)(18). However, the effect of resveratrol on HE and neurobehavioral alterations caused by liver dysfunction has not been studied, particularly in a model of acute liver failure.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Resveratrol on Thioacetamide-induced Liver Damage in Rat Models

et al. 2020

View full text Add to dashboard Cite

Background: The current treatments of liver diseases are not sufficiently effective, and there has been no therapy that can successfully prevent liver failure and its complications. Previous studies have suggested that resveratrol could inhibit the progression of hepatic diseases based on its antioxidative and anti-inflammatory potentials. Objectives: The present study evaluated the hepato-protective effects of resveratrol in thioacetamide (TAA)-induced acute liver damage in rats using neurobehavioral and biochemical parameters. Methods: Forty-eight healthy adult Wistar rats were divided into four groups: C1: healthy control group, C2: non-treated liver failure, E1: liver failure treated with resveratrol 5 mg/kg/day, and E2: liver failure treated with resveratrol 10 mg/kg/day. Aspartate aminotransferase/alanine aminotransferase (AST/ALT), alkaline phosphatase (Alk), total bilirubin (TB), and plasma-ammonia (NH4) were analyzed, and histopathological evaluations of the specimens were carried out after sacrificing the models. Hepatic encephalopathy (HE) grading, open-field, elevated plus arms, and forced-swimming tests were performed in the study. Results: The resveratrol-treated groups had lower serum concentrations of NH4, ALT, and AST than the C2 group (P < 0.05). The pathological evaluations demonstrated that resveratrol-treated groups had better outcomes in inflammatory cell infiltration, apoptosis, vacuolization, liver tissue necrosis, and liver damage stage than the C2 group (P < 0.05). They also showed lower grades of HE, higher locomotor activity (open-field test), and diminished levels of depression (forced-swimming) when compared to the C2 group (P < 0.05). Conclusions: Resveratrol supplementation can improve liver damage as AST, ALT, NH4, and tissue damages were decreased after administering the agent in TAA-induced liver damage. Resveratrol can also improve the neurobehavioral manifestations in animal models of liver failure.

show abstract

Section: Discussionsupporting

confidence: 56%